(0.21%) 5 142.50 points
(0.15%) 38 498 points
(0.31%) 17 901 points
(0.05%) $83.89
(0.73%) $1.937
(0.30%) $2 354.20
(0.62%) $27.71
(2.15%) $941.95
(-0.18%) $0.933
(-0.34%) $10.99
(-0.31%) $0.798
(1.24%) $93.02
-1.24% £ 7.16
Live Chart Being Loaded With Signals
GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally...
Stats | |
---|---|
Volumen de hoy | 92 180.00 |
Volumen promedio | 366 983 |
Capitalización de mercado | 12.67M |
EPS | £0 ( 2023-09-20 ) |
Próxima fecha de ganancias | ( £0 ) 2024-06-04 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -1.190 |
ATR14 | £0.202 (2.82%) |
GENinCode plc Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
GENinCode plc Finanzas
Annual | 2022 |
Ingresos: | £1.43M |
Beneficio Bruto: | £632 000 (44.20 %) |
EPS: | £-0.0580 |
FY | 2022 |
Ingresos: | £1.43M |
Beneficio Bruto: | £632 000 (44.20 %) |
EPS: | £-0.0580 |
FY | 2021 |
Ingresos: | £1.15M |
Beneficio Bruto: | £593 000 (51.39 %) |
EPS: | £-0.0432 |
FY | 2020 |
Ingresos: | £960 801 |
Beneficio Bruto: | £523 016 (54.44 %) |
EPS: | £-0.0111 |
Financial Reports:
No articles found.
GENinCode plc
GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico